What is the main purpose of these amendments to Boston Scientific's credit agreements?

The primary purpose of the amendments is to modify the 'restricted payments' clauses in both the February Term Loan Credit Agreement and the Revolving Credit Agreement. This modification allows Boston Scientific to make scheduled quarterly cash dividend payments on its recently issued 5.50% Mandatory Convertible Preferred Stock, Series A, and other similar convertible securities.

How do these amendments impact Boston Scientific's financial flexibility?

These amendments enhance Boston Scientific's financial flexibility by explicitly permitting dividend payments on its mandatory convertible preferred stock. This removes a potential restriction and clarifies the company's ability to meet its obligations to preferred shareholders, suggesting confidence in its ongoing cash flow.

Are these amendments related to new debt or borrowing?

No, these amendments do not appear to involve the incurrence of new debt or borrowing. Instead, they are modifications to existing credit facilities to allow for specific types of payments, namely dividends on preferred stock, that might have been restricted under the original terms.

What is the significance of the 5.50% Mandatory Convertible Preferred Stock, Series A?

The 5.50% Mandatory Convertible Preferred Stock, Series A, is a class of preferred stock that requires conversion into common stock under certain conditions. The ability for BSX to pay dividends on this stock, as enabled by these amendments, is important for maintaining good standing with preferred stockholders and managing its capital structure.

BSX 8-K: Material Agreements

Summary

Boston Scientific Corporation (BSX) filed an 8-K on May 29, 2020, detailing amendments to its credit agreements, specifically the February Term Loan Credit Agreement and the Revolving Credit Agreement. These amendments are primarily aimed at addressing restrictions on restricted payments. The company has secured permission to make regular quarterly cash dividend payments and other limited cash payments on its recently issued 5.50% Mandatory Convertible Preferred Stock, Series A, and other similar capital stock. This change is significant as it provides flexibility in capital allocation, particularly concerning dividends on preferred stock, which could be viewed positively by investors seeking clarity on the company's ability to meet its obligations to preferred shareholders. These amendments are crucial for maintaining financial flexibility during a period of potential uncertainty. By amending the restricted payments covenants, BSX demonstrates proactive management of its financial obligations. The ability to pay dividends on its mandatory convertible preferred stock suggests confidence in its near-term cash flow generation and operational stability. Investors should note that these amendments do not appear to involve new debt incurrence but rather modifications to existing credit facilities to accommodate planned dividend payments.

Key Highlights

1Boston Scientific (BSX) amended its $1.000 billion 364-day term loan credit agreement dated February 27, 2020.
2BSX also amended its $2.750 billion revolving credit agreement dated December 19, 2018.
3The core purpose of both amendments is to modify the 'restricted payments' covenants.
4These modifications permit the payment of regularly scheduled quarterly cash dividends on the 5.50% Mandatory Convertible Preferred Stock, Series A.
5The amendments also allow for other limited cash payments on the company's mandatory convertible preferred stock and other similar capital stock.
6These changes provide greater financial flexibility regarding dividend payments on preferred stock.
7The amendments were entered into on May 28, 2020.

BOSTON SCIENTIFIC CORP 8-K Report, Material Agreement (May 29, 2020)

Summary

Key Highlights

Frequently Asked Questions